EMA Authorised: Tryngolza (olezarsen sodium) — Swedish Orphan Biovitrum AB (publ)

View source ↗

Summary

The European Medicines Agency authorised Tryngolza (olezarsen sodium) from Swedish Orphan Biovitrum AB (publ) for hyperlipoproteinemia type I under orphan drug …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyperlipoproteinemia Type

Drugs mentioned

• TRYNGOLZA (olesarsen sodium)

Snippet

Status: Authorised. Therapeutic area: Hyperlipoproteinemia Type I. MAH: Swedish Orphan Biovitrum AB (publ). Decision date: 01/12/2025. Orphan medicine